Gilead­'s Kite earns sec­ond-line win for CAR-T Yescar­ta, set­ting up a bat­tle over ear­li­er blood can­cer pa­tients

Bris­tol My­ers Squibb shook the CAR-T field ear­li­er this month with a break­through win in ear­li­er-line blood can­cer pa­tients with the promise of chang­ing the par­a­digm in cell ther­a­py care. Now, old­er com­peti­tor Yescar­ta is un­cork­ing re­sults of its own in that sought-af­ter pop­u­la­tion — and this time it ac­tu­al­ly has some da­ta to show.

Kite’s Yescar­ta boost­ed event free sur­vival over a stan­dard of care reg­i­men of physi­cians’-choice sal­vage ther­a­py fol­lowed by high-dose chemo plus a stem cell trans­plant in sec­ond-line re­lapsed or re­frac­to­ry large B cell lym­phoma pa­tients in a win the drug­mak­er is call­ing a “land­mark” in CAR-T care, Kite said in a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER